Investment and growth of the main line of health reform

 Investment lines: health reform and growth
2008   02  22   05:43  China Securities Journal
font: medium and small
2008 pages palette, the pharmaceutical industry in medical reform to achieve sustainable growth, driven by the proposed super-equipped medical unit. Our investment advice is: look for good healthcare benefits and growth companies.
the rising demand for the release of medical reform is a huge future development of the pharmaceutical industry driving force, with product advantages, the scale advantage of the needs of pharmaceutical companies will benefit from the heavy volume, and the growth of serious illness will be more types of medication was recommended for Double-Crane Pharmaceutical (love stocks, market, information), the Baiyun Mountain. the backbone of medical devices Enterprises will also benefit from increased rural hospitals and urban community hospitals, the increase in orders for construction to obtain recommended medical Xinhua (love stocks, market, information). In addition, we are very optimistic about the pharmaceutical distribution industry, recommended Medicines shares (shares love, quotes, information) and the same medicine (love stocks, market, information).
addition to the catalytic medical reform, we in the in common with first-class R & D, innovation, or through new products, new markets are expected to achieve rapid growth in the future. Recommended companies include: dual-Heron Pharmaceutical (love stocks, market, information), Henry Medicine ( Love shares, market, information), Huahai (love stocks, market, information), Hong edge medicine (love stocks, market, information), Tasly (love stocks, market, information) and Guangzhou Pharmaceutical (Love shares, market, information).
Double-Crane Pharmaceutical (600062): Business Focus infusion, cardiovascular medicine and endocrine therapy. from the first three quarters of 2007, look at the financial statements, the company's business has been a large infusion driven health care reform, a substantial increase of 33% year on year. the future of high margin infusion plastic bottle plastic bags will be gradually occupied the high-end market, the traditional glass bottles transfusion will also benefit rural and urban communities in the rise of the market.'s recent issuance of Plastic bags are used to expand the plastic bottle infusion of capacity, complete industrial upgrading, and solve the problems related party transactions, financial situation more clearly health.
Baiyun Mountain (000 522): General pharmaceutical species-rich large pharmaceutical companies, has been with amoxicillin, Compound Danshen Tablets, ceftriaxone and other varieties of 8 billions of dollars, the company will adjust the product structure next to the independent pricing, high margin products tilt. The company has a size advantage and brand advantages, promising health care reform after the introduction of tendering procurement of chemicals and the company, driven by sales of proprietary Chinese medicines.
Medicines shares (600,511): The texture is very good pharmaceutical distribution companies, the main business of rapid growth, steadily improved gross margin and costs have continued to decline in the rate of performance beyond expectation.'s business focus is a pure business development sales, and high-end products by the agent to avoid homogeneous competition, future of the company's commercial business to maintain a compound growth rate of more than 25%. refined higher margin business of local anesthetic agents, and showed good growth trend began .2008 tax rate from 33% to 25% of the performance of the company will also be thickening. In the current rapid business growth, do not rule out the possibility of extensive growth.
same medicine (000 028): pharmaceutical distribution companies in South China, covering Guangdong, Guangxi and Guangdong, Guangxi, Shenzhen .2007 successful integration of improved operational and management efficiency, I believe that integration will bring greater effect in 2008 reflected. the company's commercial business focus Great variety, thanks to the expansion of the overall drug concentration and improve circulation. subsidiary of Jun caused the production of cephalosporin medicine use of new production lines to capacity has been increased about 3 times, the future advantages of using the scale of sales channels will further thickening of the performance of the company.
Xinhua Medical (600,587): the leading national medical device companies, the main production equipment, disinfection and sterilization, radiation diagnosis and treatment equipment, pharmaceutical equipment, medical environmental protection equipment, surgical instruments, disposable medical supplies, etc. . disinfection and sterilization equipment, the company's market share in China in the first place, radiological diagnosis and treatment equipment sales are also among the best. the next two years, as the government primary health care and public health efforts to increase, relative to companies with foreign enterprises relative to the price advantage and the size of the domestic small businesses, the quality advantage of government procurement will be the biggest beneficiaries of the medical enterprise.
double Heron Pharmaceutical (002038): is growing fast, features a very distinct biological system drug companies, with second-tier product strategy of overseas exports will further enhance the performance of the company. If the drug can be obtained production approval in 2008, will bring another engine of growth for the company.
Hengrui Medicine (600276): antitumor agents leading enterprises, with the largest production base of anticancer drugs, accounting for about 12.5% domestic market share. The main products of docetaxel and oxaliplatin is still in high growth interval, the growth rate in 2008 is expected to reach more than 35%, respectively, and 25% or more . second-line antineoplastic irinotecan after the promotion period in 2006, also began to fast on the amount of expected sales of billions of dollars in 2007, further expanded in 2008. In addition, the company is actively planning the implementation of overseas markets, the current API has 4 varieties through the FDA, the ongoing preparation of the certification, we believe that open up overseas markets will lead the company into a new stage of development, bringing the expected results may be super.
Huahai (600 521): The company being a changes in field of industrial upgrading, the main product Plymouth drugs through capacity expansion and transfer to the preparations for the company a new growth engine. Plymouth products are anti-hypertensive drug, has maintained a strong global demand the company's production capacity based on the original 60% increase will further meet the market demand, and achieving economies of scale to reduce costs, estimated 2007-2009 CAGR of 35% or more .2007 July by anti-AIDS drugs nevirapine U.S. FDA certification, open the domestic formulations market certification through the precedent of international norms, the entry of more products for the company, paving the way. the company's industrial upgrade is well underway, but this will be a more long-term work, we believe that specific benefits will be reflected after 2009. Meanwhile, anti-hypertension drugs Sartan market capacity has improved rapidly in space. is expected to more than 2009 companies rely on to achieve results highlight the rapid growth of products.
Kang edge medicine (600557): R & D strength of the modern Chinese enterprise, first-line products, reserve a number of new products, the future development of the enterprise motivated.
Tasly (600 535): CSDP 10% price increase in 2007, and in September entered a expected price increases in 2008 and the market capacity will be double drive, significantly enhance the company profitability. The new products, multiple powder injection products listed. powder injection is the trend of Chinese medicine injection upgrade, Tasly is expected to become standards in this area were .2007 affected by the new accounting standards, will start Tasly of the arrogance and Shanghai Tasly of 54.39 million yuan management fee charged to all affected the performance of the company, future growth can be expected.
Guangzhou Pharmaceutical (600332): the company's biggest bright spot is that the rapid growth of Wong Lo Kat, compared to the billions of red cans sales of Wong Lo Kat , Tetra Pak Wong Lo Kat there is a large market space, is expected to 2008,2009 can maintain the growth rate of more than 50%. In addition, Xiaoke Pill, soothe the nerves Bunao sales of liquid and well Huatuo Zaizao pills, the future will maintain the 15% growth. commercial company's joint venture with United United States and China have improved the company's financial condition, prospects for a broader joint venture is the product of cooperation the two sides. (Wang Qian)